作者: Maame Dankwah-Quansah , Antonio M. Omuro
DOI: 10.1007/978-94-007-0344-5_31
关键词:
摘要: Malignant gliomas, including anaplastic astrocytomas, oligodendrogliomas and glioblastomas are aggressive primary brain tumors associated with dismal prognosis. The standard treatment for consists of temozolomide radiotherapy, but virtually all patients recur, a fatal disease outcome. Molecular targeted therapy has been the focus attention in development new treatments malignant gliomas. Many signaling pathways that could potentially be have described, P13k/Akt/mTOR, Ras/MAPK, others. Unfortunately, first generation trials gliomas disappointing. While strategies targeting angiogenesis through VEFGR pathway inhibition shown promising activity, results single agent several other drugs largely negative. Current research is focusing on combination different agents multi-targeted treatments, as well patient selection based pre-existing molecular characteristics. In this chapter we review issues encountered previously conducted, future venues.